PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces the launch of SoPRano, a high-performance set of screening tools to accelerate the drug discovery process for pharmaceutical and biotechnology companies.
SoPRano’s key advance is to use the proven principle of surface plasmon resonance (SPR) and make it available in high throughput on a standard plate-reader, without the need for costly specialist equipment. PharmaDiagnostics already offers ADME/PK and custom assay development products and services, and is working with leading research groups to introduce regular further platform enhancements in new application areas.
Label-free screening is currently an area of great interest in the pharmaceutical research market. PharmaDiagnostics’ approach stands out as all other available label-free technologies require expensive dedicated equipment that restricts both breadth of application and compound throughput. PharmaDiagnostics’ localized surface plasmon resonance technology (LSPR) is broadly enabling, with easy to use protocols, and is applicable to a range of assays for both small molecule and antibody screening and characterization. For the first time, label-free screening can be applied in high throughput applications.
“With SoPRano, PharmaDiagnostics is providing label-free screening for a much broader range of researchers,” said Dr David Ricketts, CEO at PharmaDiagnostics. “Early customer feedback has been extremely positive. This product launch at Screening Europe and our new corporate website and online SoPRano facility demonstrates PharmaDiagnostics’ commitment to develop and enhance SoPRano and bring our customers real value.”
“After our recent USD 3.5 million fundraising, the launch of SoPRano is another significant step forward in the development of PharmaDiagnostics’ business,” added Ricketts.
Filed Under: Drug Discovery
